Results 11 to 20 of about 536 (130)

Efficacy of daclatasvir and asunaprevir for viral hepatitis С in two donor lung recipients [PDF]

Российский журнал гастроэнтерологии, гепатологии, колопроктологии, 2018
Aim. To estimate efficacy and safety of direct antiviral drugs for hepatitis C treatment in donor lung recipients. Key points. The first cases in Russian literature and one of the first-ever cases of hepatitis C treatment by direct antiviral agents in ...
D. T. Abdurakhmanov, Ye. . Sidorova, I. N. Tikhonov, N. A. Mukhin, V. T. Ivashkin   +4 more
doaj   +2 more sources

Asunaprevir, a protease inhibitor for the treatment of hepatitis C infection [PDF]

Therapeutics and Clinical Risk Management, 2014
Ivan Gentile,1 Antonio Riccardo Buonomo,1 Emanuela Zappulo,1 Giuseppina Minei,1 Filomena Morisco,2 Francesco Borrelli,1 Nicola Coppola,3 Guglielmo Borgia1 1Section of Infectious Diseases, 2Section of Gastroenterology, Department of Clinical Medicine and ...
Gentile I, Buonomo AR, Zappulo E, Minei G, Morisco F, Borrelli F, Coppola N, Borgia G   +7 more
doaj   +3 more sources

Single nucleotide polymorphisms associated with elevated alanine aminotransferase in patients receiving asunaprevir plus daclatasvir combination therapy for chronic hepatitis C.

PLoS ONE, 2019
AimsDrug-induced liver damage characterized by serum alanine aminotransferase (ALT) elevation often occurs in direct-acting antiviral (DAA) combination therapy for chronic hepatitis C virus (HCV) infection.
Keizo Kato, Noritomo Shimada, Masanori Atsukawa, Hiroshi Abe, Norio Itokawa, Yoshihiro Matsumoto, Rie Agata, Akihito Tsubota   +7 more
doaj   +2 more sources

Outcomes for Cirrhotic Patients with Hepatitis C Virus 1b Treated with Asunaprevir and Daclatasvir Combination

Annals of Hepatology, 2017
Background: The efficacy and safety of asunaprevir + daclatasvir combination therapy for treatment of hepatitis C virus (HCV) in compensated cirrhotic patients was not fully evaluated in real-world.
Akihiro Tamori, Hoang Hai, Sawako Uchida-Kobayashi, Masaru Enomoto, Ritsuzo Kozuka, Hiroyuki Motoyama, Etsushi Kawamura, Atsushi Hagihara, Yuga Teranishi, Kanako Yoshida, Hiroyasu Morikawa, Yoshiki Murakami, Norifumi Kawada   +12 more
doaj   +2 more sources

Evaluation of the effi cacy and safety of the use of asunaprevir in combination with daclatasvir in patients with chronic hepatitis С: a prospective cohort study [PDF]

Медицинский вестник Юга России, 2017
Objective: to give assessment of the effi cacy and safety of using asunaprevir in combination with daclatasvir in patients with chronic hepatitis C (HCV) with severe fi brosis and cirrhosis.
Elena B. Romanova, Yuri M. Ambalov, Dmitry V. Sizyakin, Irina Y. Khomenko, Oleg I. Khomenko, Karina R. Titiryan   +5 more
doaj   +2 more sources

Successful Treatment for Chronic Hepatitis C-Autoimmune Hepatitis Overlap Syndrome due to Daclatasvir and Asunaprevir

Case Reports in Gastroenterology, 2017
Persistent hepatitis C virus (HCV) infection may induce autoimmune diseases and chronic hepatitis C is sometimes accompanied by autoimmune hepatitis (AIH).
Ayumi Sugiura, Shuichi Wada, Hiromitsu Mori, Takefumi Kimura, Yoshiaki Matsuda, Naoki Tanaka, Eiji Tanaka, Kendo Kiyosawa   +7 more
doaj   +2 more sources

Addition of ribavirin to daclatasvir plus asunaprevir for chronic hepatitis C 1b patients with baseline NS5A resistance-associated variants improved response

Journal of the Formosan Medical Association, 2017
Daclatasvir is a nonstructural protein 5A inhibitor with potent activity against hepatitis C virus genotypes 1–6 in vitro, and asunaprevir is a nonstructural protein 3 protease inhibitor with activity against genotypes 1, 4, 5, and 6.
Chun-Ming Hong, Chun-Jen Liu, Shiou-Hwei Yeh, Pei-Jer Chen   +3 more
doaj   +2 more sources

Hyperbilirubinemia without Transaminitis during Combined Therapy with Daclatasvir and Asunaprevir

Case Reports in Gastroenterology, 2016
Daclatasvir (DCV) and asunaprevir (ASV) are direct-acting antivirals (DAAs) used in the treatment of chronic hepatitis C virus (HCV) infection. Combined therapy with DCV and ASV shows high efficacy and safety even in patients with cirrhosis.
Hayato Baba, Kazuto Tajiri, Kohei Nagata, Kengo Kawai, Masami Minemura, Toshiro Sugiyama   +5 more
doaj   +2 more sources

Daclatasvir Plus Asunaprevir Dual Therapy for Chronic HCV Genotype 1b Infection: Results of Turkish Early Access Program

Annals of Hepatology, 2017
Background: Daclatasvir and asunaprevir dual therapy is approved for the treatment of HCV genotype 1b infection in several countries. Aim: To evaluate the efficacy and safety of daclatasvir and asunaprevir dual therapy in Turkish patients.
Seyfettin Köklü, Iftihar Köksal, Ulus Salih Akarca, Ayhan Balkan, Rahmet Güner, Aylin Demirezen, Memduh Sahin, Sila Akhan, Reşat Ozaras, Ramazan Idilman   +9 more
doaj   +2 more sources

Hemoglobin Decrease with Iron Deficiency Induced by Daclatasvir plus Asunaprevir Combination Therapy for Chronic Hepatitis C Virus Genotype 1b. [PDF]

PLoS ONE, 2016
BACKGROUND:Decreased hemoglobin (Hb) level has been supposed to be a relatively rare side effect of a combination therapy against hepatitis C virus that consists of the NS5A inhibitor daclatasvir (DCV) and the NS3/4A protease inhibitor asunaprevir (ASV).
Nobuyuki Matsumoto, Hiroki Ikeda, Ryuta Shigefuku, Nobuhiro Hattori, Tsunamasa Watanabe, Kotaro Matsunaga, Tetsuya Hiraishi, Tomohiro Tamura, Yohei Noguchi, Yasunobu Fukuda, Toshiya Ishii, Chiaki Okuse, Akira Sato, Michihiro Suzuki, Fumio Itoh   +14 more
doaj   +2 more sources